Summary Sequential methotrexate (Mtx) absorption studies were undertaken in 127 children undergoing treatment for childhood non-T acute lymphoblastic leukaemia (ALL) to determine whether serum drug concentration, clearance and dosage affect event free survival (EFS). Higher serum concentration and area under the plasma concentration curve (AUC) were not associated with an improved EFS. Methotrexate clearance was not found to be of prognostic significance.
Although methotrexate (Mtx) has been used in the treatment of childhood ALL for over 40 years and is one of the major drugs utilised in the continuing or maintenance therapy of this disease, the optimum method of administration is still unknown. Wide variations in absorption occur following oral administration with resultant upredictable serum concentrations (Freeman Narrod, 1962; Kearney et al., 1979; Craft et al., 1980; Pinkerton et al., 1980; Balis et al., 1983) and it has been suggested that the lower and more variable serum concentrations after oral Mtx may account for some relapses in children with ALL. Therefore it may be that intramuscular (IM) Mtx could reduce variability and improve prognosis.
To explore this possibility a study was commenced in 1979 at the Hospital for Sick Children, Great Ormond Street in which patients were randomised to receive oral or IM Mtx during maintenance therapy .
Drug doses have previously been related to event free survival (EFS) in childhood ALL and other malignancies with patients receiving half doses having a higher incidence of disease recurrence than those on full dosage (Pinkel et al., 1971; Gaynon et al., 1987) . From this it has been extrapolated that higher serum concentrations of cytotoxic drugs are associated with a greater chance of prolonged disease remission. In patients with ALL given oral Mtx, higher I h serum concentrations have been related to an improved EFS (Craft et al., 1980) . Variability in serum concentration following intravenous high dose Mtx has been shown to be associated with disease free survival, a more rapid clearance and a lower steady state concentration inferring a poor prognosis (Evans et al., 1984; Evans et al., 1986) . In order to relate serum Mtx concentration to relapse free survival in childhood ALL sequential Mtx absorption studies have been carried out on 127 children with ALL. The overall outcome, differences in Mtx pharmacokinetics between IM and oral administration and inter-and intraindividual variability in absorption have already been reported Pearson et al., 1987) . This paper relates the pharmacokinetics and dosage of Mtx and the 6-mercaptopurine (6-MP) dosage to EFS in childhood ALL.
Patients and methods
Between 1979 and 1982 all children with non-T ALL receiving therapy at the Hospital for Sick Children, Great Ormond Street, London, were treated according to the PLOD protocol (Gushaw & Miller, 1978; Mills, S. unpublished results) .
For each absorption study the median concentration was noted and the area under the serum concentration curve for the first 24 h (AUC24) was determined using the linear trapezoid method. For seven patients calculations of the AUC was not possible as not all data points were available. For those receiving IM Mtx the clearance was calculated (dose divided by AUC24) assuming 100% bioavailability.
Children had the percentage of the recommended protocol dose of 6-MP and Mtx (in mg m-2) that they were actually prescribed calculated. This and the mean ANC was determined for each of the eight 12 week periods during continuing therapy. This was only possible in the 117 children over the age of 2 years at the start of continuing therapy as younger children had cranial irradiation delayed until after their second birthday and received intrathecal Mtx at monthly intervals till then and on these occasions systemic Mtx was omitted.
Median Mtx pharmacokinetic measurements, Mtx and 6-MP doses and ANC were used regardless of the number of determinations made. The pattern of change of drug dosage and ANC over the eight courses was considered in the subset of (>2 years old) patients who completed therapy (94 patients) using analysis of variance).
Preliminary univariate analysis was carried out to assess the influence of each variable using the Cox proportional hazard model to give an estimate of the regression coefficient and its corresponding confidence interval. The assumption of proportionality of hazards was tested by fitting a time dependent covariate for the coefficient in the form (z -z*) (t -t*) where z and t are covariates, * denotes their respective means and when the coefficient was found to be significant, the hazard rate was expressed as a function of time and the covariate. A positive coefficient indicated that higher values of the explanatory variable were associated with an increase in the risk of relapse, and a negative coefficient indicated high values associated with a decrease in the risk of relapse. A non-zero time coefficient would imply an increasing (coefficient >0) or decreasing (coefficient <0) hazard with time. The effect of covariates on the risk of relapse was assessed for the three time periods; during therapy (the first 2 years), after completion of treatment (more than 2 years after diagnosis) and the entire period.
Multivariate analysis using a Cox proportional hazard model with forward stepwise selection was carried out to select the subset of variables most related to EFS. At each step, no variable with a P value greater than 0.02 (0.01 in children under the age of 2 years) was entered and the variable with the smallest P was entered. The analysis was repeated on the subset of >2 years old to include drug dosage and ANC.
For presentation of results, covariates were dichotomised at the median value. The survival functions were compared using the Breslow Log-Rank test. The number of patients used in each analysis is shown in Table I .
Data management and description was carried out using SAS statistical software and statistical analysis using BMDP statistical software. Graphical output was using Ghost-80 graphics library.
Permission for the study was granted by the Joint Committee of Ethical Practice of the Hospital for Sick Children and the Institute of Child Health.
Results

Pharmacokinetics of Mtx absorption
The median Mtx concentration on 127 patients studied was 0.225 JM (range 0.03-0.56AM) and the median AUC was 4.3 AM h-' (range 0.35-9.36 JM h-l) (Table IT) . For those patients randomised to receive IM Mtx the median clearance was 6.77 1 h-2 (range 4.26-12.53). Those patients who received Mtx via an IM route had a significantly higher median concentration (P<0.001) and AUC24 (P<0.001).
Dosage of Mtx and 6-MP and ANC One hundred and seventeen children who were over the age of 2 at the commencement of continuing therapy were prescribed a median of 94% of the protocol dose of Mtx with a range of 30-107%. Children who received IM Mtx received significantly lower doses than those receiving the drug by the (18) 101 (30) 120 (48) Mtx absorption data All variables, patients 111 (17) 94 (29) 111 (46) > 2 years at diagnosis oral route (P = 0.001). During the 2 years of therapy the Mtx dose administered during each of the eight courses fell significantly (P = 0.002) but the reduction was similar for both oral and IM groups (P = 0.9).
The overall median dose of 6-MP administered also varied with a median 103.5% (range 31-155.5%). There was no difference in the percentage dose of 6-MP administered between children receiving IM or oral Mtx (P = 0.94). In contrast to Mtx there was a significant trend for patients to receive increasingly more 6-MP during therapy (P = 0.001). Again this was the same for both groups (P = 0.53). There was no relationship between the dose of methotrexate and 6-mercaptopurine.
The dose of vincristine and prednisone was constant in all patients. The median ANC was 2.55 x I0' 1-(range of 1.10-4.85) with no difference between those patients receiving oral or IM Mtx (P = 0.97) and there was no trend during therapy (P = 0.9). As expected the median ANC was significantly correlated with the median percentage 6-MP dose (P = 0.001) and to a much lesser extent with the median Mtx dose.
Neither age, sex nor presenting white cell count were correlated with the percentage administered dose of 6-MP and Mtx or with the absolute neutrophil count.
Factors affecting EFS Seventy-four patients are still in remission. There were 29 bone marrow, seven central nervous system, nine testicular and three other relapses. Five patients had concomitant central nervous system and bone marrow relapse. Two patients died in remission from infection. Figures I and 2 ).
Patients with a higher white cell count and older children had an increased rate of relapse on therapy (P < 0.001, P= 0.01).
After completion of therapy the risk of leukaemic relapse was greater in those children who had received lower than the median Mtx dose (P = 0.001) (Figure 3 ) or higher 6-MP dose (P = 0.03) (Figure 4) . The effect of these variables on leukaemic relapse became less important with increasing time. Age and white cell count were not factors affecting relapse after completion of therapy.
The results of the multivariate analyses are shown in Table  IV . The addition of other covariates to the model after white cell count did not significantly produce a better model for relapses on therapy. However, with relapses after completion of therapy the percentage median Mtx dose had some importance on survival.
As sample sizes of patients with isolated bone marrow, testicular and central nervous system relapse were small, it was not possible to obtain statistically significant results when examining these subgroups. Therefore only the EFS could be related to their considered variables. Any subdivision of patients into prognostic subcategories by white cell count and age also was not possible because of the small numbers of relapses in each subgroup.
Discussion
Previous studies have shown that there is great interindividual variation in the pharmacokinetics of Mtx when given by mouth or intramuscularly to children with ALL (Freeman Narrod, 1962; Kearney et al., 1979; Craft et al., 1980; Pinkerton et al., 1980; Balis et al., 1983; Pearson et al., 1987) . There has been speculation that differences in Mtx handling could account for some of the otherwise unexplained relapses which occur in children with ALL and an early study reported that patients with a higher I h level after an oral dose had a better chance of survival (Craft et al., 1980) . The present study was designed to test whether there was an association between Mtx pharmacokinetic parameters and EFS. We have already reported that in this study IM Mtx was associated with higher peak concentrations and AUC but that interand intrapatient variability was no less than when given orally (Pearson et al., 1987) . On examining the EFS in terms of Mtx pharmacokinetics it has been shown that higher peak concentrations and AUC are not associated with improved survival either when oral and IM are combined or separately. This is in contrast to the findings from two previous studies from St Jude's Children's Hospital (Evans et al., 1984; Evans et al., 1986) where slower Mtx clearances and higher steady state serum concentrations were initially associated with an improved EFS rate. However, with further follow up this survival advantage was lost (Evans, 1989) . In these studies the dose of Mtx administered was greater than in the present study. The degree of Mtx polyglutamate formation has been shown to vary with different doses and exposure times to Mtx (Chabner et al., 1985) and this may explain the differences in these findings. Figure 3 Event free survival in 117 patients who were over the age of two at the commencement of maintenance therapy and had the % of the Mtx dose which they received calculated. Children were grouped according to the percentage of the prescribed Mtx dose. Significance value (P = 0.1) for all events, (P = 0.44) for events during therapy, (P = 0.001) for events occurring after discontinuation of therapy. Figure 4 Event free survival in 1 17 patients who had 6-mercaptopurine dosage calculated and who were over the age of two at the commencement of maintenance therapy. Significance value (P = 0.94) for all events, (P = 0.18) events during the therapy and (P = 0.03) for events occurring off therapy. The lack of any association between EFS and median Mtx levels is in conflict with a previous Medical Research Council (MRC) study (Craft et al., 1980) where there was a significant correlation between 1 h levels and outcome. The MRC study was one of the earliest in this field and suffered from various problems. The method of Mtx administration was not standardised, it was a multicentre study and the results were reported at an early stage. With time these significant findings have not persisted (Craft A.W. -personal observation). The present study was carried out in a single institution, with standardised method of Mtx administration and all patients have been followed for at least 7 years. Therefore the present findings are considerably more robust.
Despite each child having only three Mtx absorption studies and intraindividual variability in Mtx absorption (Pearson et al., 1987) (Silberman et al., 1985) . Those patients who received a lower dose of 6-MP due to greater toxicity had a greater EFS. The better survival in the MRC UKALL VIII trial compared to previous studies has been attributed to the sustained use of maximally tolerated dose of 6-MP and Mtx (Medical Research Council, 1986) . In other cancers half doses of drugs have been similarly shown to be associated with increased relapse rate (Bonadona & Valagussa, 1981; Hiyniuk & Bush, 1984; Carde et al., 1983) .
Recent evidence suggests that intracellular metabolism of 6-MP and Mtx may affect myelotoxicity and leukaemia relapse. Red blood cell intracellular 6-thioguanine nucleotides have been related to ANC 2 weeks later (Lennard et al., 1983) . Also children who have higher red blood cell 6-thioguanine nucleotide concentrations have a higher EFS (Lennard et al., 1990 ). Thus patients who tolerate low doses of 6-MP and Mtx may be those who have higher intracellular concentrations of metabolites. This study does not address the important variables of patient and physician compliance in drug administration (Smith et al., 1979) . It did not compare differences between prescribed and received doses of orally administered cytotoxic drugs. Failure in compliance may be a factor accounting for some relapses in childhood ALL, however specifically designed studies are needed to investigate this problem.
The overall randomised study of oral vs IM Mtx during continuing therapy of childhood ALL showed that IM Mtx produced no advantage in EFS and was associated with a greater incidence of neutrotoxicity, infectious complications and patients discomfort . Also IM Mtx did not appear to benefit any subgroup of patients. IM Mtx does produce higher peak concentrations and AUC, however there is no less variability than with oral Mtx. Although the unknown variable of patient compliance in drug administration is overcome with the administration by this route, both the higher serum concentrations and certainty of administration were not associated with improved leukaemia relapse free survival in this trial.
